Answers are grounded in this paper and cite their sources.
Vasculopathy is an increasingly recognised partner to inflammatory rheumatological disease. Raynaud’s phenomenon (RP) is generally considered a benign vascular manifestation. The natural history of systemic sclerosis (SScl), however, suggests that we underestimate the significance of RP in this context. RP occurs in approximately 90% of SScl patients, often decades before the diagnosis is recognised, and is a harbinger of generalised vasculopathy. Pulmonary arterial hypertension (PAH) is another manifestation of this process, which occurs in approximately 12% of SScl patients [1]. PAH accounts for approximately 50% of mortality in limited SScl and accounts for approximately 7% of mortality in diffuse SScl. It is probable that the vasculopathic processes underlying RP and PAH contribute to the familiar pattern of skin, renal and gastrointestinal pathology. The emergence of effective and conveniently administered therapy for PAH increases the importance of diagnosis and monitoring of this complication. Furthermore, since many principles of PAH management translate to the management of RP, this raises the possibility that the generalised vasculopathy of SScl may also be modifiable. In the characteristic microangiopathy of SScl, luminal narrowing results from a combination of intimal proliferation, medial hypertrophy and adventitial fibrosis [2]. This leads to a state of progressive chronic organ ischaemia. Dysfunction of cellular components of the arterial wall and dysfunction of inflammatory and haemostatic systems are interrelated (Fig. 1) [3,4]. Endothelial cell dysfunction is characterised by decreased production of the vasodilators nitric oxide and prostacyclin, and by enhanced release of endothelin-1. Endothelial cell dysfunction influences the behaviour of vascular smooth muscle cells and adventitial fibroblasts, which mediate the proliferative changes and sclerosis in the sclerodermatous arterial wall. An appreciation of the crosstalk between these arterial wall components underlies the therapeutic paradigm shift from the use of pure vasodilators to agents with antiproliferative activity [5]. Endothelin receptor antagonists (ERA) are in the vanguard of these new management strategies. Phosphodiesterase (PDE) type V inhibitors, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are also promising.
No takes yet. Share an insight, caveat, or question.
Frances Hall (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: